GLPwatch

[Weight reducing and glucose reducing effects of liraglutide treatment for patients with type 2 diabetes].

Ugeskr Laeger · 2011

Last updated 2026-05-28

Liraglutide, a GLP-1 drug, lowered blood sugar control (HbA1c) by 1-2% and reduced weight, lipids, and blood pressure in people with type 2 diabetes. Most side effects were mild stomach issues that went away within weeks, and severe low blood sugar was rare. However, long-term effects of the drug are not yet known.

AI summary of the abstract below.

JournalUgeskr Laeger, 2011
Citations0
Relative citation ratio0.00
NIH percentile0
Molecules liraglutide
Conditions studied Type 2 Diabetes, Obesity

Abstract

Treatment with glucagon-like peptide-1 analogues including liraglutide is a new treatment option for patients with type 2 diabetes. Treatment with liraglutide decreases HbA1c by 1-2%, and additionally liraglutide has a reducing effect on weight, lipids and blood pressure. Most adverse events are related to the gastrointestinal system and most often they disappear within a few weeks. The risk of major hypoglycaemic episodes is minimal. Long term data on treatment and adverse events with liraglutide are still lacking.

Verbatim abstract via PubMed 21712007 ↗

Related research